Treatment of patients with asthma and COVID-19: ICS and biologics in hospitalised versus non-hospitalised patients
| Asthma+COVID-19 | Asthma+COVID-19 Hospitalized | p value | |
| (Jan. 1st–May 10th, 2020) | (Jan 1st–May 10th, 2020) | ||
| Patients with asthma (N=71.182) (Jan 1st, 2019–May 10th, 2020) | 1.006 | 263 | |
| Asthma+≥1 ICS (N=42.171; 59,23% of asthmatics) | 619 | 127 | <.001 |
| Asthma+≥1 Biologics (N=865; 1,21% of asthmatics)# | 18 | 2 | |
| Omalizumab (n=641) | 9 | 0 | |
| Mepolizumab (n=308) | 7 | 2 | |
| Benralizumab (n=98) | 2 | 0 | |
| Reslizumab (n=26) | 1 | 0 |
#54% of the patients treated with Mepolizumab had been previously treated with Omalizumab; 65% of patients treated with Benralizumab had previously been treated with Omalizumab and 35% with Mepolizumab. Most of the patients treated with Reslizumab had been previously treated with Omalizumab and Mepolizumab.